AIM AIM ImmunoTech Inc.

0.5
+0.01  (+2%)
Previous Close 0.49
Open 0.49
Price To Book 0.46
Market Cap 2,439,431
Shares 4,839,181
Volume 302,861
Short Ratio 0.33
Av. Daily Volume 648,054
Stock charts supplied by TradingView

NewsSee all news

  1. AIM ImmunoTech Provides Comprehensive Clinical Trials Update With Major Inflection Points Identified

    Well Capitalized to Complete Current Ampligen Clinical Trials Following $10M in Capital Raises Plus $15M Recently Awarded by DOD to Roswell Park and Moffitt for Ampligen-Related Breast Cancer TrialsOCALA, FL / ACCESSWIRE

  2. AIM ImmunoTech, Inc. Announces Pricing of $8 Million Public Offering

    OCALA, FL / ACCESSWIRE / September 25, 2019 / AIM ImmunoTech, Inc. (NYSE:AIM) (the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of

  3. AIM ImmunoTech Inc. Announces a Second DoD Award, This One of $8.3 Million, to Fund Phase 2 Clinical Trial to Study Ampligen as Part of a New Treatment for Brain-Metastatic Breast Cancer at the Moffitt Cancer Center

    New Ampligen-Related Strategy for Treating Advanced Breast Cancer Helps Earn 'Breakthrough Award'OCALA, FL / ACCESSWIRE / September 24, 2019 / AIM ImmunoTech (NYSE:AIM), an immuno-pharma company focused on the

  4. AIM ImmunoTech's Ampligen Receives Clearance from FDA for Exportation to Argentina for the Treatment of Severe Chronic Fatigue Syndrome

    Important Milestone to Commercial Launch in Argentina AchievedOCALA, FL / ACCESSWIRE / September 24, 2019 / AIM ImmunoTech (NYSE:AIM), an immuno-pharma company focused on the research and development of therapeutics to

  5. AIM ImmunoTech Inc. Announces the U.S. Department of Defense's Award of $6.42M to Roswell Park Comprehensive Cancer Center to Study Ampligen as Part of a New Treatment of Brain-Metastatic Breast Cancer

    New Ampligen-Related Strategy for Treating Advanced Breast Cancer Earns 'Breakthrough Award'OCALA, FL / ACCESSWIRE / September 19, 2019 / AIM ImmunoTech Inc. (NYSE:AIM), an immuno-pharma company focused

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

CRL February 4, 2013.
Ampligen
CFS
Phase 1 data due around 2Q 2020.
Ampligen, Intron A, celecoxib and pembrolizumab
Triple-Negative Breast Cancer
Phase 2 interim data due around 2Q 2020.
Ampligen, Intron A, and celecoxib
Colorectal cancer
Phase 2 interim data due around 4Q 2020.
Ampligen, cisplatin and pembrolizumab
Ovarian cancer
Phase 2 trial to commence enrolment in 4Q 2019.
Ampligen, Intron A
Prostate Cancer
Phase 1 interim data likely around January/February 2020 timeframe.
Ampligen plus Intron A
Ovarian cancer

Latest News

  1. AIM ImmunoTech Provides Comprehensive Clinical Trials Update With Major Inflection Points Identified

    Well Capitalized to Complete Current Ampligen Clinical Trials Following $10M in Capital Raises Plus $15M Recently Awarded by DOD to Roswell Park and Moffitt for Ampligen-Related Breast Cancer TrialsOCALA, FL / ACCESSWIRE

  2. AIM ImmunoTech, Inc. Announces Pricing of $8 Million Public Offering

    OCALA, FL / ACCESSWIRE / September 25, 2019 / AIM ImmunoTech, Inc. (NYSE:AIM) (the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of

  3. AIM ImmunoTech Inc. Announces a Second DoD Award, This One of $8.3 Million, to Fund Phase 2 Clinical Trial to Study Ampligen as Part of a New Treatment for Brain-Metastatic Breast Cancer at the Moffitt Cancer Center

    New Ampligen-Related Strategy for Treating Advanced Breast Cancer Helps Earn 'Breakthrough Award'OCALA, FL / ACCESSWIRE / September 24, 2019 / AIM ImmunoTech (NYSE:AIM), an immuno-pharma company focused on the

  4. AIM ImmunoTech's Ampligen Receives Clearance from FDA for Exportation to Argentina for the Treatment of Severe Chronic Fatigue Syndrome

    Important Milestone to Commercial Launch in Argentina AchievedOCALA, FL / ACCESSWIRE / September 24, 2019 / AIM ImmunoTech (NYSE:AIM), an immuno-pharma company focused on the research and development of therapeutics to

  5. AIM ImmunoTech Inc. Announces the U.S. Department of Defense's Award of $6.42M to Roswell Park Comprehensive Cancer Center to Study Ampligen as Part of a New Treatment of Brain-Metastatic Breast Cancer

    New Ampligen-Related Strategy for Treating Advanced Breast Cancer Earns 'Breakthrough Award'OCALA, FL / ACCESSWIRE / September 19, 2019 / AIM ImmunoTech Inc. (NYSE:AIM), an immuno-pharma company focused

  6. AIM ImmunoTech Names Ellen Lintal as New Chief Financial Officer

    OCALA, FL / ACCESSWIRE / September 16, 2019 / AIM ImmunoTech Inc. (NYSE:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency

  7. AIM ImmunoTech Inc. to Present at the Fall Investor Summit on September 16th-17th in New York City

    OCALA, FL / ACCESSWIRE / September 13, 2019 / AIM ImmunoTech Inc. (NYSE:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency

  8. AIM ImmunoTech Announces Progress Toward Opening of Breast Cancer Study at Roswell Park Comprehensive Cancer Center

    OCALA, FL / ACCESSWIRE / September 10, 2019 / AIM ImmunoTech Inc., (NYSE:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency